David Charles Lubner

Board Director

Director

Arcellx, Inc.POINT Biopharma Global Inc.Dyne Therapeutics, Inc.Braveheart Bio, Inc.

Insider activity · 24 months1 buy1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 1 saleFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 1 buy · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (2 ops.)

€892k

▼ Sales (1 ops.)

€387k

Latest filing published 07 Aug 2026 for Braveheart Bio, Inc., €868k. Read the official filing

Filing timeline

BuySale

David Charles Lubner

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

David Charles Lubner: trading record in brief

Filings by David Charles Lubner span 6 companies, the busiest being Arcellx, Inc., Ra Pharmaceuticals, Inc. and Dyne Therapeutics, Inc. Over a trading history stretching from 1 February 2019 to 7 August 2026, the count stands at 13 filings.

The open-market side counts 2 purchases for €892k alongside 1 sale for €387k. Purchases outweigh sales by €505k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant and 2 option exercises. 2026 to date brings 1 purchase and 1 sale.

The latest filing, published on 7 August 2026, reports an open-market purchase of €868k in Braveheart Bio, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.